Holmes A - Search Results

1

Stress and Fear Extinction.

Maren S, Holmes A. Maren S, et al. Among authors: holmes a. Neuropsychopharmacology. 2016 Jan;41(1):58-79. doi: 10.1038/npp.2015.180. Epub 2015 Jun 24. Neuropsychopharmacology. 2016. PMID: 26105142 Free PMC article. Review.

2

Targeted gene mutation approaches to the study of anxiety-like behavior in mice.

Holmes A. Holmes A. Neurosci Biobehav Rev. 2001 May;25(3):261-73. doi: 10.1016/s0149-7634(01)00012-4. Neurosci Biobehav Rev. 2001. PMID: 11378180 Review.

3

Deficits in trace cued fear conditioning in galanin-treated rats and galanin-overexpressing transgenic mice.

Kinney JW, Starosta G, Holmes A, Wrenn CC, Yang RJ, Harris AP, Long KC, Crawley JN. Kinney JW, et al. Among authors: holmes a. Learn Mem. 2002 Jul-Aug;9(4):178-90. doi: 10.1101/m.49502. Learn Mem. 2002. PMID: 12177231 Free PMC article.

4

Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter.

Holmes A, Yang RJ, Murphy DL, Crawley JN. Holmes A, et al. Neuropsychopharmacology. 2002 Dec;27(6):914-23. doi: 10.1016/S0893-133X(02)00374-3. Neuropsychopharmacology. 2002. PMID: 12464448

5

Galanin peptide levels in hippocampus and cortex of galanin-overexpressing transgenic mice evaluated for cognitive performance.

Wrenn CC, Marriott LK, Kinney JW, Holmes A, Wenk GL, Crawley JN. Wrenn CC, et al. Among authors: holmes a. Neuropeptides. 2002 Dec;36(6):413-26. doi: 10.1016/s0143-4179(02)00111-7. Neuropeptides. 2002. PMID: 12507436

6

Galanin GAL-R1 receptor null mutant mice display increased anxiety-like behavior specific to the elevated plus-maze.

Holmes A, Kinney JW, Wrenn CC, Li Q, Yang RJ, Ma L, Vishwanath J, Saavedra MC, Innerfield CE, Jacoby AS, Shine J, Iismaa TP, Crawley JN. Holmes A, et al. Neuropsychopharmacology. 2003 Jun;28(6):1031-44. doi: 10.1038/sj.npp.1300164. Epub 2003 Apr 9. Neuropsychopharmacology. 2003. PMID: 12700679

7

Mice lacking the serotonin transporter exhibit 5-HT(1A) receptor-mediated abnormalities in tests for anxiety-like behavior.

Holmes A, Yang RJ, Lesch KP, Crawley JN, Murphy DL. Holmes A, et al. Neuropsychopharmacology. 2003 Dec;28(12):2077-88. doi: 10.1038/sj.npp.1300266. Neuropsychopharmacology. 2003. PMID: 12968128

8

Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders.

Holmes A, Heilig M, Rupniak NM, Steckler T, Griebel G. Holmes A, et al. Trends Pharmacol Sci. 2003 Nov;24(11):580-8. doi: 10.1016/j.tips.2003.09.011. Trends Pharmacol Sci. 2003. PMID: 14607081 Review.

9

Loss of brain-derived neurotrophic factor gene allele exacerbates brain monoamine deficiencies and increases stress abnormalities of serotonin transporter knockout mice.

Ren-Patterson RF, Cochran LW, Holmes A, Sherrill S, Huang SJ, Tolliver T, Lesch KP, Lu B, Murphy DL. Ren-Patterson RF, et al. Among authors: holmes a. J Neurosci Res. 2005 Mar 15;79(6):756-71. doi: 10.1002/jnr.20410. J Neurosci Res. 2005. PMID: 15672416

10

Galanin impairs performance on learning and memory tasks: findings from galanin transgenic and GAL-R1 knockout mice.

Rustay NR, Wrenn CC, Kinney JW, Holmes A, Bailey KR, Sullivan TL, Harris AP, Long KC, Saavedra MC, Starosta G, Innerfield CE, Yang RJ, Dreiling JL, Crawley JN. Rustay NR, et al. Among authors: holmes a. Neuropeptides. 2005 Jun;39(3):239-43. doi: 10.1016/j.npep.2004.12.026. Neuropeptides. 2005. PMID: 15944016 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results